News

A gastroenterologist discusses some of the findings regarding COVID-19 and gastrointestinal symptoms.

The approval is based on findings from a phase 2 clinical trial.

Less than 1% of nearly 500,000 hospitalized patients required kidney replacement therapy.

Treatment with the PCSK9 Inhibitor did not increase risk of safety events, including new-onset diabetes.

The goal is to begin delivering safe and effective COVID-19 vaccines to the Amerian people.

REGENXBIO also announced the scheduling of a phase 2 trial testing RGX-314 for wet AMD.

Guideline adoption could lead to more use of thrombolytic therapy.

The risk of depression or clinically relevant depressive symptoms did not significantly differ between a group taking Vitamin D and a group taking a placebo.

Additional monitoring is needed among patients receiving opioid therapy.

Tiotropium plus olodaterol is more effective for patients with COPD compared with LABA plus inhaled corticosteroids.

MagVenture TMS Therapy can be used as adjunctive therapy to other OCD treatments.

In a comparison with manual human grading, investigators find machine learning model produced no statically significant differences in Dice coefficients.

In a cross-sectional study among CAD patients, investigators found that 30.3% of heart team treatment recommendations diverged from original consultation.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

A team of researchers have added 3 new modifiable risk factors to a list of 9 known factors that increase the risk of developing dementia.

An expert in Alzheimer disease describes some of the struggles dementia patients might be going through during the COVID-19 pandemic.

New data shows an adherence to troponin testing could complement optimized care.

Dupilumab significantly reduces exacerbation rates in patients with asthma compared to standard of care.

In a study presented virtually at ATS 2020, investigators find 15 mg of the study drug resulted in a 43% decrease in FeNO.

A new case study  assesses biopsy and autopsy tissues to characterize pathological patterns in suspected EVALI cases .

Investigators found a 22% reduction in clinical decline at the 78-week cutoff in the intent to treat population in EMERGE who received high-dose aducanumab, with a similar reduction seen in the opportunity to complete population.

The study paves the way for prospective multi-institutional randomized control trials to further re-enforce the safe use of direct oral anticoagulants in patients with obesity.

In a study presented at ATS 2020, investigators test 3 different dosing regimens of tezepelumab in asthma patients with both high and low levels of IL-5 and IL-13.

An analysis of chest X-rays suggests people of color are more likely to have increased disease severity.

A famed virologist weighs in on the country's earliest shortcomings—and how they can still be resolved today.

The indication limits the new opioid to clinical setting use—no take-home prescriptions.

A one-time intramuscular dose of the investigative drug was linked to reduced medical attention and hospitalizations related to RSV.

A new study has great implications for equitable access to primary care for older adults during the pandemic.